Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (previously presented) A pharmaceutical composition comprised of an aqueous solution comprising synthetic peptide in admixture with a polyol; wherein the synthetic peptide is an HIV fusion inhibitor; wherein the synthetic peptide is in a final concentration in the pharmaceutical composition of not less than 70 mg/ml and not more than 500 mg/ml; and wherein the polyol is in a final concentration of no less than 5 weight % and no more than 75 weight % of the pharmaceutical composition.

2. (previously presented) The pharmaceutical composition according to claim 1, wherein the synthetic peptide is in a final concentration in the pharmaceutical composition of not less than 100 mg/ml and not more than 250 mg/ml.

3. (previously presented) The pharmaceutical composition according to claim 1, wherein the polyol is in a final concentration of no less than 10 weight % and no more than 50 weight % of the pharmaceutical composition.

4. (previously presented) The pharmaceutical composition according to claim 1, wherein the polyol comprises polyethylene glycol.

5. (previously presented) The pharmaceutical composition according to claim 1, further comprising a pharmaceutically acceptable carrier additional to the polyol.

6. (previously presented) A method of treating HIV infection comprising administering to an HIV-infected individual a pharmaceutical composition according to claim 1.

7. (previously presented) A pharmaceutical composition comprised of an aqueous solution comprising synthetic peptide in admixture with a polyol; wherein the synthetic peptide is an HIV fusion inhibitor; wherein the synthetic peptide is in a final concentration in the pharmaceutical composition of not less than 100 mg/ml and not

more than 250 mg/ml; and wherein the polyol is in a final concentration of no less than 10 weight % and no more than 50 weight % of the pharmaceutical composition.

8. (previously presented) The pharmaceutical composition according to claim 7, wherein the polyol comprises polyethylene glycol.

9. (previously presented) The pharmaceutical composition according to claim 7, further comprising a pharmaceutically acceptable carrier additional to the polyol.

10. (previously presented) A method of treating HIV infection comprising administering to an HIV-infected individual a pharmaceutical composition according to claim 7.

11. (previously presented) A synthetic peptide-containing pharmaceutical composition as a unit dose, wherein the pharmaceutical composition comprises an aqueous solution comprising: (a) a polyol present as a pharmaceutically acceptable carrier in an amount not less than 5 weight % and not more than 75 weight % of the pharmaceutical composition as a unit dose; and (b) synthetic peptide comprising an HIV fusion inhibitor in a final concentration of the pharmaceutical composition of not less than 70 mg/ml and not more than 500 mg/ml.

12. (previously presented) The synthetic peptide-containing pharmaceutical composition according to claim 11, wherein the synthetic peptide is in a final concentration in the pharmaceutical composition of not less than 100 mg/ml and not more than 250 mg/ml.

13. (previously presented) The synthetic peptide-containing pharmaceutical composition according to claim 11, wherein the polyol is in a final concentration of no less than 10 weight % and no more than 50 weight % of the pharmaceutical composition.

14. (previously presented) The synthetic peptide-containing pharmaceutical composition according to claim 11, wherein the polyol comprises polyethylene glycol.

15. (previously presented) The synthetic peptide-containing pharmaceutical composition according to claim 11, further comprising a pharmaceutically acceptable carrier additional to the polyol.

16. (previously presented) A method of treating HIV infection comprising administering to an HIV-infected individual a synthetic peptide-containing pharmaceutical composition according to claim 11.

17. (previously presented) A synthetic peptide-containing pharmaceutical composition as a unit dose, wherein the pharmaceutical composition comprises an aqueous solution comprising: (a) a polyol present as a pharmaceutically acceptable carrier in an amount not less than 10 weight % and not more than 50% of the pharmaceutical composition as a unit dose; and (b) synthetic peptide comprising an HIV fusion inhibitor in a final concentration of the pharmaceutical composition of not less than 100 mg/ml and not more than 250 mg/ml.

18. (previously presented) The synthetic peptide-containing pharmaceutical composition according to claim 17, wherein the polyol comprises polyethylene glycol.

19. (previously presented) The synthetic peptide-containing pharmaceutical composition according to claim 17, further comprising a pharmaceutically acceptable carrier additional to the polyol.

20. (previously presented) A method of treating HIV infection comprising administering to an HIV-infected individual a synthetic peptide-containing pharmaceutical composition according to claim 17.

21. (previously presented) A method of treating HIV infection comprising administering to an HIV-infected individual a pharmaceutical composition according to claim 5.

22. (previously presented) A method of treating HIV infection comprising administering to an HIV-infected individual a pharmaceutical composition according to claim 9.

23. (previously presented) A method of treating HIV infection comprising administering to an HIV-infected individual a synthetic peptide-containing pharmaceutical composition according to claim 15.

24. (previously presented) A method of treating HIV infection comprising administering to an HIV-infected individual a synthetic peptide-containing pharmaceutical composition according to claim 19.

25. (new) The pharmaceutical composition according to claim 9, wherein the pharmaceutically acceptable carrier, additional to the polyol, comprises an aqueous alcohol.

26. (new) The synthetic peptide-containing pharmaceutical composition according to claim 15, wherein the pharmaceutically acceptable carrier, additional to the polyol, comprises an aqueous alcohol.

27. (new) The synthetic peptide-containing pharmaceutical composition according to claim 19, wherein the pharmaceutically acceptable carrier, additional to the polyol, comprises an aqueous alcohol.

28. (new) A method of treating HIV infection comprising administering to an HIV-infected individual a pharmaceutical composition according to claim 25.

29. (new) A method of treating HIV infection comprising administering to an HIV-infected individual a synthetic peptide-containing pharmaceutical composition according to claim 26.